ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2220

Impact of Fibromyalgia on DAS28 in Patients with Rheumatoid Arthritis

Aman Sharma1, Ashish Aggarwal2, Eyal Kedar3, Mary Bach4 and Shounak Lahiri5, 1Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER, Chandigarh, Chandigarh, India, 3St. Lawrence Health System, Potsdam, NY, 4VA Puget Sound Health Care System, Seattle, WA, 5Twistle Inc., Albuquerque, NM

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  To estimate the prevalence of secondary fibromyalgia (FM) in patients with RA and its effect on the disease activity score (DAS28) in a tertiary care teaching hospital.

Methods:  Patients aged above 18 years who had been diagnosed with rheumatoid arthritis (RA) as per the ACR/EULAR criteria 2010 were included in the study. Fibromyalgia (FM) was diagnosed using the ACR 1990 criteria. Patients with incomplete clinical data and above 75 years were excluded. Laboratory and clinical findings were entered in a structured format. DAS28 was assessed using ESR and supplemented with CRP, only if ESR was not available. Statistical analyses were performed using SPSS v16 software. The study was approved by the Institutional Ethics Committee of PGIMER, Chandigarh.

Results:  A total of 371 subjects were recruited with a mean age of 46 (±12.3) years. The study population followed normal distribution in age with a median of 46 years and mode of 45 years. The male to female ratio was 1:5.4. The prevalence of FM was 18.1% amongst RA patients (67/372). In patients with secondary FM 92.5% were female compared to 82.6% without FM. 65.7% patients with FM had a disease duration of greater than 5 years compared to 46.9% patients without FM. 71.6% of patients with FM had high disease severity compared with only 43.9% patients without FM. The average DAS28 score was significantly higher [(p<0.001); 95% CI: 1.2 – 3.7] in patients with secondary FM (5.68±1.49) compared to those without FM (4.92±1.62). In sub-analyses of independent variables of DAS28, tender joint counts were significantly higher [(p<0.001); 95% CI: 3 – 8.8] in patients with FM (17.90) as compared to RA patients without FM (11.98). Also, the patients’ global health scores were worse [p<0.001; 95% CI: 5.5 – 21.6] in RA patients with FM. Swollen joint count and ESR values were comparable in both the groups.

Conclusion: The present study reports that 18.1% of the RA patients had associated FM. TJC and GH of patients are affected by the co-existing FM. The study advocates the development of new outcome measures that are more objective and depend upon reliable laboratory biomarkers/ultrasound evidence of synovitis for assessing the disease activity of RA patients.


Disclosure: A. Sharma, None; A. Aggarwal, None; E. Kedar, None; M. Bach, None; S. Lahiri, None.

To cite this abstract in AMA style:

Sharma A, Aggarwal A, Kedar E, Bach M, Lahiri S. Impact of Fibromyalgia on DAS28 in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-fibromyalgia-on-das28-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-fibromyalgia-on-das28-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology